Trial Profile
Phase 1 Open-Label, Dose-Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intravitreal 4D-110 in Patients With Choroideremia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs 4D-110 (Primary)
- Indications Choroideraemia
- Focus Adverse reactions
- Sponsors 4D Molecular Therapeutics
- 18 Jan 2023 Planned End Date changed from 1 May 2023 to 1 Jun 2027.
- 18 Jan 2023 Planned primary completion date changed from 1 Nov 2021 to 1 Jun 2024.
- 12 May 2022 According to a 4D Molecular Therapeutics media release, updates from this trial expected in the first half of 2023.